natgillin/translations-raw huggingface dataset:
Caution is recommended when MAVENCLAD is used in elderly patients, taking into account the potential greater frequency of decreased hepatic or renal function, concomitant diseases and other medicinal therapies. 
Pri uporabi zdravila MAVENCLAD pri starejših bolnikih se priporoča previdnost, pri čemer je treba upoštevati možno večjo pogostnost zmanjšanega delovanja jeter ali ledvic, sočasne bolezni in druge oblike zdravljenja.
Such medicines include alemtuzumab, daclizumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta, natalizumab or teriflunomide. 
Takšna zdravila vključujejo alemtuzumab, daklizumab, dimetilfumarat, fingolimod, glatiramer acetat, interferon beta, natalizumab ali teriflunomid.
- Push your tablet(s) through the blister and swallow immediately. 
- Tableto(i) potisnite skozi pretisni omot in jo(ju) takoj pogoltnite.
Lymphopenia is known to be dosedependent (see sections 4.4 and 4.8). 
Za limfopenijo se ve, da je odvisna od odmerka (glejte poglavji 4.4 in 4.8).
MAVENCLAD does not affect your ability to drive or use machines. 
Zdravilo MAVENCLAD ne vpliva na vašo sposobnost vožnje in upravljanja strojev.
Based on human experience with other substances inhibiting DNA synthesis, cladribine could cause congenital malformations when administered during pregnancy. 
Na podlagi izkušenj pri ljudeh z drugimi učinkovinami, ki zavirajo sintezo DNA, lahko kladribin povzroči kongenitalne malformacije, če ga jemljejo nosečnice.
The tablets must be taken with water, and swallowed without chewing. 
Tablete je treba jemati z vodo in zaužiti cele, brez žvečenja.
Treatment with MAVENCLAD has been shown to reduce flare-ups of symptoms and to slow down progression of disability. 
Izkazalo se je, da zdravljenje z zdravilom MAVENCLAD zmanjša izbruhe simptomov in upočasni napredovanje prizadetosti.
The safety and efficacy of MAVENCLAD in patients below the age of 18 years have not been established. 
Varnost in učinkovitost zdravila MAVENCLAD pri bolnikih, mlajših od 18 let, nista bili dokazani.
The use of MAVENCLAD with interferon beta results in an increased risk of lymphopenia. 
Uporaba zdravila MAVENCLAD v kombinaciji z interferonom beta privede do povečanega tveganja za limfopenijo.
The mean duration of MS prior to study enrolment was 8.7 years, and the median baseline neurological disability based on Kurtzke Expanded Disability Status Scale (EDSS) score across all treatment groups was 3.0 (range 0 to 6.0). 
Povprečno trajanje MS pred vključitvijo v študijo je bilo 8,7 let, mediana izhodiščna ocena nevrološke prizadetosti po Kurtzkejevi Razširjeni lestvici nevrološke prizadetosti (Expanded Disability Status Scale - EDSS) v vseh skupinah zdravljenja je bila 3,0 (razpon 0 do 6,0).
Moderate or severe renal impairment (creatinine clearance <60 mL/min) (see section 5.2). 
Zmerna ali huda okvara delovanja ledvic (očistek kreatinina < 60 ml/min) (glejte poglavje 5.2).
Pregnancy and breast-feeding (see section 4.6). 
Nosečnost in dojenje (glejte poglavje 4.6).
Initiation of treatment with MAVENCLAD must be postponed for 4 to 6 weeks to allow for the full effect of vaccination to occur. 
Uvedbo zdravljenja z zdravilom MAVENCLAD je treba odložiti za 4 do 6 tednov, da nastopi polni učinek cepljenja.
Oriented polyamide (OPA)/aluminium (Al)/polyvinyl chloride (PVC) - aluminium (Al) blister sealed in a cardboard wallet and fixed in a child-resistant outer carton. 
Pretisni omot iz orientiranega poliamida (OPA)/aluminija (Al)/polivinilklorida (PVC) - aluminija (Al), zavarjen v kartonski zgibanki in pritrjen v za otroke varni škatli.
Teratogenicity/adverse pregnancy outcomes, to ensure that female patients of child bearing potential / partners of male patients receiving Mavenclad: a. 
Teratogenost/neželeni izidi nosečnosti, za zagotavljanje, da bolnice v rodni dobi/partnerke bolnikov, ki se zdravijo z zdravilom Mavenclad: a.
In this extension study, 806 patients received either placebo or a cumulative dose of cladribine 3.5 mg/kg (in a regimen similar to that used in CLARITY) over the 96-week study period. 
V tej podaljšani študiji je 806 bolnikov prejemalo bodisi placebo ali skupni odmerek kladribina 3,5 mg/kg (v podobnem režimu kot v študiji CLARITY) v obdobju 96-tedenske študije.
In mice, there were no effects on fertility or the reproductive function of offspring. 
Pri miših niso opazili učinkov na plodnost ali sposobnost razmnoževanja potomstva.
In vitro studies indicate that cladribine efflux is only minimally P-gp related. 
Študije in vitro kažejo, da je efluks kladribina le minimalno povezan s P-gp.
Your doctor may delay treatment, or interrupt it, until the infection clears up. 
Morda bo zdravnik zdravljenje preložil ali ga prekinil, dokler se okužba ne pozdravi.
The primary apoptosis-inducing mechanism of action of Cd-ATP has direct and indirect actions on DNA synthesis and mitochondrial function. 
Primarni mehanizem delovanja Cd-ATP, ki inducira apoptozo, ima posreden in neposreden vpliv na sintezo DNA in delovanje mitohondrijev.
It is known that the more medicine you take the less lymphocytes may be present in your body, resulting in lymphopenia (see section 4). 
Znano je, da z naraščanjem količine zdravila pada število limfocitov v vašem telesu, kar lahko povzroči limfopenijo (glejte poglavje 4).
The recommended cumulative dose of MAVENCLAD is 3.5 mg/kg body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. 
Priporočeni skupni odmerek zdravila MAVENCLAD je 3,5 mg/kg telesne mase v 2 letih, ki se da kot 1 ciklus zdravljenja z 1,75 mg/kg na leto.
Blood transfusions 
Transfuzija krvi
If you change from MAVENCLAD to other MS treatments, talk to your doctor. 
Pri prehodu z zdravila MAVENCLAD na drugo zdravljenje MS se pogovorite z zdravnikom.
Use of oral cladribine in patients weighing less than 40 kg has not been investigated. 
Uporabe peroralnega kladribina pri bolnikih s telesno maso pod 40 kg niso raziskali.
Number of tablets to take Year 1 treatment course 
Število tablet, ki jih morate jemati 1. leto ciklusa zdravljenja
Women who become pregnant under therapy with MAVENCLAD should discontinue treatment. 
Ženske, ki med zdravljenjem z zdravilom MAVENCLAD zanosijo, morajo prekiniti zdravljenje.
Because of the rapid and extensive intracellular and tissue distribution, haemodialysis is unlikely to eliminate cladribine to a significant extent. 
Zaradi hitre in ekstenzivne intracelularne porazdelitve in porazdelitve v tkivih je malo verjetno, da bi hemodializa kladribin odstranila v pomembni meri.
The metabolite 2-chloroadenine was a minor metabolite both in plasma and in urine, e.g. accounting only for ≤3% of plasma parent drug exposure after oral administration. 
Presnovek 2-kloroadenin je bil manj pomemben presnovek tako v plazmi kot v urinu, predstavlja npr. samo ≤ 3 % izpostavljenosti matičnemu zdravilu v plazmi po peroralni uporabi.
White, round, biconvex tablets of 8.5 mm diameter, engraved with 'C' on one side and '10' on the other side. 
Bele, okrogle, bikonveksne tablete s premerom 8,5 mm z vtisnjeno oznako 'C' na eni strani in '10' na drugi.
Swallow tablet(s) with water. 
Tableto(-i) pogoltnite z vodo.
A supportive study in patients treated with cladribine as an add-on to interferon-beta vs. placebo + interferon-beta also included a limited number of patients with secondary progressive MS (26 patients). 
Podporna študija pri bolnikih, zdravljenih s kladribinom dodatno k interferonu beta v primerjavi s placebom + interferonom beta, je vključevala omejeno število bolnikov s sekundarno progresivno MS (26 bolnikov).
Blood tests 
Krvne preiskave
Cladribine reduces CD19+ B cells and CD16+/CD56+ natural killer cells, which also recover faster than CD4+ T cells. 
Kladribin zmanjša število celic B CD19+ in naravnih celic ubijalk CD16+/CD56+, ki si prav tako hitreje opomorejo kot celice T CD4+.
Relapsing-remitting MS 
Recidivno remitentna MS
The MAH shall ensure that in each MS where Mavenclad is marketed, all prescribers and patients who are expected to prescribe / use Mavenclad are provided with: 
Imetnik dovoljenja za promet bo zagotovil, da bodo v vsaki državi članici, kjer je zdravilo Mavenclad na trgu, vsi zdravniki, za katere se pričakuje, da bodo zdravilo Mavenclad predpisovali, in bolniki, ki ga bodo uporabljali, prejeli:
th percentile for disability progression was reached between 16 and 23 weeks, while for the cladribine groups it was not reached during the entire study. 
Za placebo je bil 10. percentil za napredovanje prizadetosti dosežen med 16 in 23 tedni, medtem ko ga skupina s kladribinom v času študije ni dosegla.
Pick up carton with the opening instructions facing up. 
Primite škatlo tako, da so navodila za odpiranje usmerjena navzgor.
Based on a population pharmacokinetic analysis including patients with normal renal function and with mild renal impairment, total clearance in patients with mild renal impairment (CLCR = 60 mL/min) is expected to decrease moderately, leading to an increase in exposure of 25%. 
Na podlagi populacijskih analiz farmakokinetike, ki je zajela bolnike z normalnim delovanjem ledvic in z blago okvaro delovanja ledvic, se pričakuje zmerno znižanje celokupnega očistka pri bolnikih z blago ledvično okvaro (CLCR = 60 ml/min), kar povzroči povečanje izpostavljenosti za 25 %.
Variations in the expression levels of DCK and 5'-NTases between immune cell subtypes may explain differences in immune cell sensitivity to cladribine. 
Odstopanja ekspresijskih ravni dCK in 5'-NTaz med podtipi imunskih celic lahko pojasnijo razlike v občutljivosti imunskih celic na kladribin.
In patients who require blood transfusion, irradiation of cellular blood components is recommended prior to administration to prevent transfusion-related graft-versus-host disease. 
Pri bolnikih, ki potrebujejo transfuzijo krvi, se pred dajanjem transfuzije priporoča obsevanje celičnih sestavin krvi, da se preprečijo s transfuzijo povezane bolezni presadka proti gostitelju (graft-versushost disease).
In patients with mild renal impairment (creatinine clearance 60 to 89 mL/min), no dosage adjustment is considered necessary (see section 5.2). 
Smatra se, da pri bolnikih z blago ledvično okvaro (očistek kreatinina 60 do 89 ml/min) prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
However, a post-hoc analysis of a mixed cohort including CLARITY and ONWARD patients, defined by a baseline EDSS score of ≥3.5 as a proxy for secondary progressive MS, showed a similar reduction in annualised relapse rate compared to patients with an EDSS score below 3. 
Vendar pa je post-hoc analiza mešane kohorte, vključno z bolniki iz študij CLARITY in ONWARD, opredeljenimi z rezultatom EDSS ≥ 3,5 kot nadomestnim parametrom za sekundarno progresivno MS, pokazala podobno zmanjšanje stopnje recidivov na letni ravni v primerjavi z bolniki z rezultatom EDSS manj kot 3.
If you take more MAVENCLAD than you should 
Če ste vzeli večji odmerek zdravila MAVENCLAD, kot bi smeli
At the level of cladribine absorption, the only conceivable interaction pathway of clinical relevance appears to be the breast cancer resistance protein (BCRP or ABCG2). 
Kaže, da je glede na na stopnjo absorpcije kladribina edino verjetna in klinično pomembna pot interakcij protein odpornosti pri raku dojke (BCRP ali ABCG2).
Distribution of dose 
Porazdelitev odmerka
Efficacy and safety of oral cladribine were evaluated in a randomised, double-blind, placebocontrolled clinical study (CLARITY) in 1,326 patients with relapsing-remitting MS. Study objectives were to evaluate the efficacy of cladribine versus placebo in reducing the annualised relapse rate (ARR) (primary endpoint), slowing disability progression and decreasing active lesions as measured by MRI. 
Učinkovitost in varnost peroralnega kladribina so ocenili v randomizirani, dvojno slepi, s placebom kontrolirani klinični študiji (CLARITY) pri 1.326 bolnikih z recidivno remitentno MS. Cilji študije so bili ocena učinkovitosti kladribina v primerjavi s placebom, opredeljena kot zmanjšanje stopnje recidiva na letni stopnji (annualised relapse rate - ARR) (primarni opazovani dogodek), upočasnitev napredovanja prizadetosti in zmanjšanje aktivnih lezij, merjeno s slikanjem z MR.
- If you lose a tablet, contact your doctor for advice. 
- Če tableto izgubite, se posvetujte z zdravnikom.
There was no difference in annualised relapse rate between patients with relapsing-remitting MS and patients with secondary progressive MS with relapses. 
Razlike v stopnji recidivov na letni ravni med bolniki z recidivno remitentno MS in bolniki s sekundarno progresivno MS z recidivi ni bilo.
Do not take MAVENCLAD at the same time as any other medicine. 
Ne jemljite zdravila MAVENCLAD sočasno z drugimi zdravili.
Read the package leaflet for further information. 
Za več informacij preberite priloženo navodilo.
Do not take the missed dose along with the next scheduled dose. 
Izpuščenega odmerka ne vzemite skupaj z naslednjim načrtovanim odmerkom.
Cladribine has no clinically meaningful inductive effect on CYP1A2, CYP2B6 and CYP3A4 enzymes. 
Kladribin nima klinično pomembnega indukcijskega učinka na encime CYP1A2, CYP2B6 in CYP3A4.
Patients should be advised to undertake standard cancer screening after Mavenclad treatment; 
je treba bolnikom svetovati, da opravijo po zdravljenju z zdravilom Mavenclad standardne presejalne preglede za raka;
In patients who have previously been treated with immunomodulatory or immunosuppressive medicinal products the mode of action and duration of effect of the other medicinal product should be considered prior to initiation of MAVENCLAD (see section 4.2). 
Pri bolnikih, ki so se predhodno zdravili z imunomodulatornimi ali imunosupresivnimi zdravili, je treba pred uvedbo zdravila MAVENCLAD upoštevati način delovanja in trajanje učinka drugega zdravila (glejte poglavje 4.2).
Other symptoms may be headache, burning, tingling, numbness or itchiness of the skin in the affected area, feeling generally unwell or feverish in the early stages of infection. 
Drugi simptomi so lahko glavobol, pekoč občutek, mravljinčenje, odrevenelost ali srbenje kože prizadetega območja, splošno slabo počutje ali nekoliko zvišana telesna temperatura v zgodnjih fazah okužbe.
You will be tested to see if you have any infections before you start MAVENCLAD treatment. 
Opravili bodo preiskave in ugotovili, ali imate kakršne koli okužbe, preden boste začeli zdravljenje z zdravilom MAVENCLAD.
A drug interaction study in MS patients showed that the bioavailability of 10 mg oral cladribine was not altered when co-administered with pantoprazole. 
Študija medsebojnega delovanja pri bolnikih z MS je pokazala, da se biološka uporabnost 10 mg peroralnega kladribina ob sočasnem dajanju pantoprazola ni spremenila.
To decrease the risk for severe lymphopenia, lymphocyte counts must be determined before, during and after cladribine treatment (see section 4.4) and strict criteria for initiating and continuing cladribine treatment must be followed (see section 4.2). 
Za zmanjšanje tveganja za hudo limfopenijo je treba pred in med zdravljenjem s kladribinom in po njem določiti število limfocitov (glejte poglavje 4.4) ter upoštevati stroge kriterije za uvedbo in nadaljevanje zdravljenja s kladribinom (glejte poglavje 4.2).
If you forget to take MAVENCLAD 
Če ste pozabili vzeti zdravilo MAVENCLAD
No increased incidence in lymphoproliferative disorders and no tumours were seen in this study. 
V tej študiji niso opazili povečane pogostnosti limfoproliferativnih bolezni, prav tako niso opazili nobenih tumorjev.
However, a baseline magnetic resonance imaging (MRI) should be performed before initiating MAVENCLAD (usually within 3 months). 
Vendar pa je treba pred uvedbo zdravila MAVENCLAD opraviti izhodiščno slikanje z magnetno resonanco (MR) (običajno v 3 mesecih).
Although PML has not been observed with MAVENCLAD, as a precaution, you may have a head MRI (magnetic resonance imaging) before you start treatment. 
Čeprav PML pri zdravilu MAVENCLAD niso opazili, vam lahko pred začetkom zdravljenja iz previdnosti naredijo slikanje glave z MR (slikanje z magnetno resonanco).
Lymphopenia may increase the risk of getting an infection. 
Limfopenija zviša tveganje za okužbo.
Each treatment course consists of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective treatment year. 
Vsak ciklus zdravljenja je sestavljen iz 2 tednov zdravljenja, enega na začetku prvega meseca in enega na začetku drugega meseca posameznega leta zdravljenja.
Studies revealed a mean volume of distribution of cladribine in the range of 480 to 490 L. The plasma protein binding of cladribine is 20%, and independent of plasma concentration. 
Študije so pokazale povprečni volumen porazdelitve kladribina v razponu od 480 do 490 l. Vezava kladribina na plazemske beljakovine je 20 % in ni odvisna od koncentracije v plazmi.
MAVENCLAD contains hydroxypropylbetadex that may interact with other medicines in your stomach. 
Zdravilo MAVENCLAD vsebuje hidroksipropilbetadeks, ki lahko medsebojno deluje z drugimi zdravili v želodcu.
MAVENCLAD is for oral use. 
Zdravilo MAVENCLAD je za peroralno uporabo.
Cd-AMP is further phosphorylated to cladribine diphosphate (Cd-ADP) and cladribine triphosphate (Cd-ATP). 
Cd-AMP se naprej fosforilira v kladribin difosfat (cladribine diphosphate - Cd-ADP) in kladribin trifosfat (cladribine triphosphateCd-ATP).
Other common side effects - may affect up to 1 in 10 people - cold sore (oral herpes) - rash - hair loss - reduction in the number of certain white blood cells (neutrophils) 
Drugi pogosti neželeni učinki - pojavijo se lahko pri največ 1 od 10 bolnikov - mehurčast izpuščaj na ustnicah (oralni herpes) - izpuščaj - izpadanje las - zmanjšanje števila nekaterih belih krvnih celic (nevtrofilcev)
Known BCRP inhibitors, which may alter the pharmacokinetics of BCRP substrates by 20% in vivo, include eltrombopag. 
Med znane zaviralce BCRP, ki lahko spremenijo farmakokinetiko substratov BCRP za 20 % in vivo, sodi eltrombopag.
If necessary, you will be vaccinated against shingles before you start treatment. 
Če bo potrebno, vas bodo pred začetkom zdravljenja cepili proti pasovcu.
It is currently unknown whether Mavenclad may reduce the effectiveness of systemically acting hormonal contraceptives. 
Trenutno ni znano, ali lahko zdravilo Mavenclad zmanjša učinkovitost sistemsko delujočih hormonskih kontraceptivov.
Do not pop the tablets out of the blister. 
Tablet ne vzemite ven iz pretisnega omota.
Table 2 shows how the total number of tablets per treatment week is distributed over the individual days. 
Preglednica 2 prikazuje porazdelitev skupnega števila tablet na teden zdravljenja po posameznih dnevih.
You will need one or more packs to provide the correct number of tablets. 
Za pravo število tablet boste potrebovali eno pakiranje ali več.
The magnitude of the effect in reducing the frequency of relapses and slowing disability progression in patients receiving the 3.5 mg/kg dose over 2 years was maintained in years 3 and 4 (see section 4.2). 
Učinka zmanjšanje pogostnosti recidivov in upočasnitev napredovanja prizadetosti pri bolnikih, ki so 2 leti prejemali odmerek 3,5 mg/kg, sta v 3. in 4. letu ostala na enaki ravni (glejte poglavje 4.2).
There is no indication that cladribine pharmacokinetics might change in a time-dependent fashion after repeated administration. 
Nič ne kaže, da bi se farmakokinetika kladribina po večkratnem dajanju lahko spremenila v odvisnosti od časa.
Make sure you have read all of the package leaflet including the step-by-step guide and keep it in a safe place. 
Navodilo za uporabo in Navodilo po korakih v celoti preberite in ju shranite na varnem mestu.
MAVENCLAD has no or negligible influence on the ability to drive and use machines. 
Zdravilo MAVENCLAD nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Table 1 Dose of MAVENCLAD per treatment week by patient weight in each treatment year 
Preglednica 1 Odmerek zdravila MAVENCLAD na teden zdravljenja glede na telesno maso bolnika v vsakem letu zdravljenja
Renal clearance exceeded the glomerular filtration rate, indicating active renal tubular secretion of cladribine. 
Ledvični očistek je presegel stopnjo glomerulne filtracije, kar kaže na aktivno ledvično tubularno izločanje kladribina.
The non-renal part of the elimination of cladribine (approximately 50%) consists of negligible hepatic metabolism and of extensive intracellular distribution and trapping of the active cladribine principle (Cd-ATP) within the targeted intracellular compartment (i.e. the lymphocytes) and subsequent elimination of intracellular Cd-ATP according to the life-cycle and elimination pathways of these cells. 
Neledvični del izločanja kladribina (približno 50 %) sestavlja zanemarljiva jetrna presnova in obsežna intracelularna porazdelitev in ujetje aktivne oblike kladribina (Cd-ATP) znotraj ciljnega intracelularnega prostora (tj. limfocitov) in kasnejšim izločanjem intracelularnega Cd-ATP glede na življenjski cikel in poti izločanja teh celic.
MAVENCLAD contains hydroxypropylbetadex, which may be available for complex formation with other medicinal products, potentially leading to an increase in bioavailability of such a product (especially medicinal products with low solubility, see section 5.2). 
Zdravilo MAVENCLAD vsebuje hidroksipropilbetadeks, ki lahko tvori komplekse z drugimi zdravili (zlasti s slabo topnimi zdravili), kar lahko povzroči zvišanje biološke uporabnosti takšnega zdravila (glejte poglavje 5.2).
The observed embryolethal and teratogenic effects are consistent with the pharmacologic mechanisms of cladribine. 
Opažena smrtnost zarodkov in teratogeni učinki so v skladu s farmakološkim mehanizmom kladribina.
A high DCK to 5'-NTase ratio favours the accumulation of Cd-ATP, making lymphocytes particularly susceptible to cell death. 
Visoko razmerje med dCK in 5'-NTazo podpira kopičenje Cd-ATP, kar naredi limfocite še posebej dovzetne za smrt celic.
While there were no effects on female fertility, reproductive function or general performance of offspring, cladribine was shown to be embryolethal when administered to pregnant mice, and the compound was teratogenic in mice (also following treatment of the males only) and rabbits. 
Čeprav na plodnost pri ženskah, sposobnost razmnoževanja ali splošno uspevanje potomstva ni bilo učinkov, je imel kladribin embrioletalne učinke, če so ga dajali brejim mišim, ter teratogene učinke pri miših (tudi samo po dajanju zdravila samcem) in kuncih.
The lymphocyte counts of more than 75% of patients returned to the normal range by week 144 from the first dose of cladribine (approximately 90 weeks after the last dose of cladribine). 
Pri več kot 75 % bolnikov se je število limfocitov do 144. tedna od prvega odmerka kladribina (približno 90 tednov po zadnjem odmerku kladribina) vrnilo v normalni razpon.
The potential consequences of P-gp induction on the bioavailability of cladribine have not been formally studied. 
Možnih posledic indukcije P-gp na biološko uporabnost kladribina niso uradno raziskovali.
When administered with a high-fat meal, cladribine absorption was delayed (median Tmax 1.5 h, range 1 to 3 h) and Cmax was reduced by 29% (based on geometric mean), while AUC was unchanged. 
Pri jemanju kladribina z obroki, ki vsebujejo veliko maščob, je bila njegova absorpcija zapoznela (mediana Tmax 1,5 h, razpon 1 do 3 h) in Cmax se je zmanjšala za 29 % (na podlagi geometrične sredine), medtem ko se AUC ni spremenila.
Cladribine cumulative dose 3.5 mg/kg (n = 433) 
Skupni odmerek kladribina 3,5 mg/kg (n = 433)
Cladribine is not a relevant substrate to cytochrome P450 enzymes and does not show significant potential to act as inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. 
Kladribin za encime citokroma P450 ni pomemben substrat in ne kaže pomembnega potenciala, da bi deloval kot zaviralec encimov CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 in CYP3A4.
INFORMATION IN BRAILLE mavenclad 
PODATKI V BRAILLOVI PISAVI mavenclad